Read from this company’s own annual reports filed with the SEC, not from a data vendor.
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $22.5M | −$203.82M |
| 2024 | $45.56M | −$241.6M |
| 2023 | $14.09M | −$176.94M |
2 more years, included withMeasure
Capital expenditure
Figures onMeasure
Financial statements
Measure opens the income statement, balance sheet and cash flow for all 5 years and 14 quarters: every figure the company filed, plus the ratio charts built from them.
Free, no card, and it does not expire. See what the paid plans add
Derived from SEC XBRL filings. Not investment advice.
Also filed under Biotechnology, ranked by how closely they sit beside NAMS.
The assistant answers from what NAMS has actually filed: 5 annual reports filed with the SEC, 79 Form 4 filings from the last year, 13F positions from the 2 tracked investors who hold it and 1 fund that holds it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.
Pressing one answers it here, from NAMS's filings and figures. One a day without an account; a free account has its own, and no card.
See every filed year for NAMS, quarter by quarter.
Ten seconds, no card, and nothing to cancel.
See all 5 filed years, not just 3
Every annual statement NAMS has ever filed, so a trend is measured over the whole record instead of a recent slice of it.
The full historyMeasure
Catch a turn before the year confirms it
Revenue, margins and cash flow quarter by quarter, where a change in direction shows up first.
Quarterly statementsMeasure
Ask why a number moved, get the filing back
Why a margin moved, where the cash went: answered from NAMS's own statements, not a guess.
Free, no card, and it does not expire.